DexCom, Inc. (DXCM) Total Return:-8.75%(TTM)
The total return cagr for DexCom, Inc. (DXCM) is -8.75% over the latest trailing 12-month period. The comparable SPY value is +24.32%. Year-to-date total return is +17.81%. Total return includes price appreciation and reinvested dividends.
Growth of $10,000 in DXCM
$265,952
(26.6x return)
Invested on Apr 14, 2005
Growth of $10,000 in SPY (S&P 500)
$93,961
(9.4x return)
Invested on Apr 14, 2005
Hypothetical Growth of $10,000
This chart illustrates the cumulative performance of a hypothetical $10,000 investment. It assumes that all dividends paid by both the stock and SPY are reinvested in additional shares on the payment date, showing the true long-term compounding impact of distributions.
Recent Performance Indicators
YTD Total Return
+17.8%
1-Year Total Return
-8.7%
Current Dividend Yield
0.00%
Price CAGR vs. Total Return CAGR
Compound Annual Growth Rate (CAGR) is shown below. The difference between price CAGR and total return CAGR is the compound contribution of dividends reinvested.
| Holding Period | Price CAGR | Total Return CAGR | Dividend Addition |
|---|---|---|---|
| 1 Year | (8.8%) | (8.8%) | — |
| 3 Years | (14.3%) | (14.3%) | — |
| 5 Years | (4.3%) | (4.3%) | — |
| 10 Years | +15.7% | +15.7% | — |
| 15 Years | +23.0% | +23.0% | — |
| 20 Years | +15.1% | +15.1% | — |
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach